Full article: Compounded glucagon like peptide 1 receptor agonists for weight loss: the direct to consumer market in Colorado The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 and the Difference Between an Evidence Gap and a Cover Up: What the entire human evidence base actually looks like, and the questions to ask next. WellFounded Founders Health & Big FDA review coming this July. Here's what athletes and patients should know about BPC 157, TB 500, and the broader peptide conversation. Always speak with your physician before starting any new protocol. #bpc157 # Injectable Peptides: Out of the Back Alley and Into the Light? Berkley Lifesciences